Wedbush Securities’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,385
| Closed | -$255K | – | 1259 |
|
|
2025
Q3 | $255K | Sell |
2,385
-300
| -11% | -$31.3K | 0.01% | 947 |
|
|
2025
Q2 | $254K | Sell |
2,685
-475
| -15% | -$35.2K | 0.01% | 928 |
|
|
2025
Q1 | $201K | Buy |
+3,160
| New | +$189K | 0.01% | 1011 |
|
|
2021
Q3 | – | Sell |
-18,035
| Closed | -$118K | – | 1242 |
|
|
2021
Q2 | $118K | Sell |
18,035
-3,965
| -18% | -$27.5K | 0.01% | 1117 |
|
|
2021
Q1 | $184K | Buy |
22,000
+10,000
| +83% | +$83K | 0.01% | 997 |
|
|
2020
Q4 | $84K | Sell |
12,000
-31,300
| -72% | -$211K | 0.01% | 844 |
|
|
2020
Q3 | $270K | Sell |
43,300
-65,800
| -60% | -$455K | 0.03% | 661 |
|
|
2020
Q2 | $511K | Buy |
109,100
+38,150
| +54% | +$177K | 0.05% | 422 |
|
|
2020
Q1 | $292K | Sell |
70,950
-10,150
| -13% | -$55.7K | 0.03% | 532 |
|
|
2019
Q4 | $466K | Buy |
81,100
+50,785
| +168% | +$222K | 0.04% | 503 |
|
|
2019
Q3 | $139K | Buy |
30,315
+6,000
| +25% | +$26.8K | 0.01% | 866 |
|
|
2019
Q2 | $124K | Sell |
24,315
-485
| -2% | -$2.96K | 0.01% | 883 |
|
|
2019
Q1 | $161K | Buy |
24,800
+10,670
| +76% | +$69.5K | 0.02% | 813 |
|
|
2018
Q4 | $127K | Buy |
+14,130
| New | +$160K | 0.02% | 738 |
|
Other funds holding VRNA
Wedbush Securities's VRNA Position: Q4 2025 in Review
Wedbush Securities sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 2,385 shares — an estimated $255K sold.
Wedbush Securities first reported a position in VRNA in Q4 2018 and held it in 14 quarters. The position peaked at $511K in Q2 2020. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Wedbush Securities reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Wedbush Securities sold 2,385 Verona Pharma shares in Q4 2025, an estimated $255K.
- Wedbush Securities first reported a position in Verona Pharma in Q4 2018 and held it in 14 quarters.
- Wedbush Securities's Verona Pharma position peaked at $511K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Wedbush Securities's 13F filing for Q4 2025, filed 12 Feb 2026.